Table 3 Hematological and non-hematological adverse events in patients with newly-diagnosed, previously untreated multiple myeloma during 47 cycles of therapy with siltuximab in combination with RVD (N=11)
Hematological toxicity type | Grade | |||||||
|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||||
No. | % | No. | % | No. | % | No. | % | |
Neutropenia | 1 | 9.1 | 1 | 9.1 | 6 | 54.5 | 3 | 16.1 |
Thrombocytopenia | 5 | 45.5 | 1 | 9.1 | 4 | 36.4 | 1 | 9.1 |
Lymphopenia | 2 | 18.2 | 1 | 9.1 | 7 | 63.6 | ||
Leukopenia | 2 | 18.2 | 2 | 18.2 | 7 | 63.6 | ||
Anemia | 6 | 54.5 | 3 | 27.3 | 2 | 18.2 | ||
Leukocytosis | 1 | 9.1 | ||||||
Non-hematological toxicity type | Grade | |||
|---|---|---|---|---|
2 | 3 | |||
No. | % | No. | % | |
Nausea | 4 | 36.4 | 2 | 18.2 |
Edema: Limbs | 1 | 9.1 | 2 | 18.2 |
Diarrhea | 3 | 27.3 | 1 | 9.1 |
Peripheral sensory neuropathy | 1 | 9.1 | 1 | 9.1 |
Maculo-papular rash | 1 | 9.1 | 1 | 9.1 |
Pneumonia | 1 | 9.1 | ||
Fatigue | 7 | 63.6 | ||
Constipation | 6 | 54.5 | ||
Paresthesia | 5 | 45.5 | ||
Myalgia | 4 | 56.4 | ||
Dizziness | 3 | 27.3 | ||
Fracture | 2 | 18.2 | ||
Upper respiratory infection | 2 | 18.2 | ||
Dyspnea | 2 | 18.2 | ||
Vomiting | 2 | 18.2 | ||
Blurred vision | 2 | 18.2 | ||
Allergic reaction | 1 | 9.1 | ||
Oral mucositis | 1 | 9.1 | ||
Dyspepsia | 1 | 9.1 | ||
Dysgeusia | 1 | 9.1 | ||
Dehydration | 1 | 9.1 | ||
Pain: Back | 1 | 9.1 | ||
Pain: Extremity | 1 | 9.1 | ||
Pain: Generalized | 1 | 9.1 | ||
Insomnia | 1 | 9.1 | ||
Head boils | 1 | 9.1 | ||
